Smithkline Beecham Corporation

Eli Lilly and Company

Johns Hopkins University

University of Michigan

Human Genome Sciences, Inc.

Other

The University of Western Ontario

Kristine Kay Kikly

Connie L Erickson-Miller

Catherine Brautigam Beidler

Derrick Ryan Witcher

Bruce Scott Bochner

Robert Schleimer

Steven M Ruben

Vishva M Dixit

Wei-Wu He

Beth Ann Strifler

Julie A Abrahamson

Christopher Donald Southan

Mark Robert Hurle

Stuart W Bright

T Esra Nutku

Anne M Knab

Mitchell Stuart Gross

Daniel Scott Girard

Earl Francis Albone

Craig A Rosen

Jian Ni

Alain Philippe Vasserot

David Matthew Marquis

Craig Duane Dickinson

Barrett Allan

John Edward Hale

Rosamund Carol Smith

Jeffrey Streetman Boyles

Radhakrishnan Rathnachalam

Gregory A Dekaban

Arthur Brown

Bomie Han

Kathleen Theresa Gallagher

Lynne Weaver

Allan Barrett

Dipak Ratilal Patel

Sudhakar Reddy Chintharlapalli

Stuart Willis Bright

Derek Ryan Witcher

Valentina Pavlovna Gelfanova

Radhakrishnam Rathnachalamm

Linda O Tobias

Provided herein are methods and uses of antibodies against ELR+ CXC chemokines for the treatment of hidradenitis suppurativa. Also provided are doses and dosing regimens for the methods and uses of antibodies against ELR+ CXC chemokines for the treatment of hidradenitis suppurativa.

PAN-ELR+ CXC chemokine antibodies for the treatment of hidradenitis suppurativa

Antibodies to human CD11d, compositions comprising such CD11d antibodies, and methods of using such CD11d antibodies for the treatment of central nervous system trauma including spinal cord injury and traumatic brain injury, as well as systemic inflammatory response following central nervous system trauma.

Anti-CD11D antibodies and uses thereof

Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.

Pan-ELR+ CXC chemokine antibodies

Bispecific antibodies are provided that bind CD20 and B-cell Activating Factor of the TNF Family (BAFF) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CD20 and BAFF. The bispecific antibodies of the invention are useful for treating autoimmune diseases including Systemic Lupus Erythematosus, Lupus Nephritis, and primary Sj&#xf6;gren's Syndrome.

Anti-CD20&#x2212; / anti-BAFF bispecific antibodies

Antibodies are provided that specifically bind seven human ELRCXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.

[object Object]

The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.

Nucleic acids encoding antibodies that bind IL-23

Pan-ELR+ CXC Chemokine Antibodies

Antibodies that bind to IL-23

Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2. These antibodies are useful as diagnostic and therapeutic reagents.

Sialoadhesin factor-2 antibodies

Methods of use of sialoadhesin factor-2 antibodies

Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., K=10M or less), a slow off rate for TNFSF13b dissociation (e.g., K=10secor less) and neutralize TNFSF13b activity in vitro and in vivo. The antibodies of the invention are useful in one embodiment for inhibiting TNFSF13b activity in a human subject suffering from a disorder in which hTNFSF13b activity is detrimental. Nucleic acids encoding the antibodies of the present invention, as well as, vectors and host cells for expressing them are also encompassed by the invention.

Method to treat using antagonistic anti-hTNFSF13b human antibodies

The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease.

Anti-IL-23 antibodies

Antagonistic anti-hTNFSF13b human antibodies

Growing community of inventors

Fortville, IN, United States of America

Kristine Kay Kikly